.png){kind=logo}
Who Are We ?
Malaria Vaccine Pilot Evaluation-Case Control (MVPE-CC) is a collaborative project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) that brings together a multidisciplinary consortium of leading African clinical trial centres in partnership with European and global institutions with complementary expertise and proven track record.
Why Are We Doing This ?
In 2019, the Ministries of Health in Malawi, Ghana and Kenya with support from the World Health Organization (WHO) introduced on pilot basis the RTS,S malaria vaccine. The vaccine implementation is accompanied by an independent evaluation
(Malaria Vaccine Pilot Evaluation), to assess the safety of RTS,S in routine use, the feasibility of reaching children with the recommended four-dose schedule, and the impact of the vaccine at population level to inform global
policy recommendation.
Through the WHO-coordinated Malaria Vaccine Implementation Programme (MVIP) more than 700,000 children have been vaccinated in the three countries. The surveillance established for the MVIP provides an opportunity for
case control studies to be conducted to address additional questions about vaccine impact, that cannot be answered directly through the cluster randomized design. Additionally, new data bring into question the importance of the
4th dose in the recommended schedule. The MVIP Programme Advisory Group recommended case-control studies, as a priority, to address these questions to inform policy. Data for the case-control studies will be collected as part of
the ongoing Malaria Vaccine Pilot Evaluation.
Strategy (How Are We Doing This? What makes it Unique?)
Incidence-density case-control designs will be used with community controls recruited concurrently with cases, matched on date of birth and neighbourhood. This type of design allows the incidence rate ratio associated with the exposure (RTS,S vaccination) to be estimated.
Impact
The project will make important contributions to policy decisions about a potential wider use of the malaria vaccine in sub-Saharan Africa and will help maximize acceptability, uptake and impact, if recommended for use. The project also aims to promote, 1) use of case-control approaches by the Expanded Programme of Immunization (EPI) and malaria control programmes in high-burden countries, and 2) strengthening capacity by training malaria and immunizations programme managers in the use of case-control approaches to monitor and assess safety and effectiveness of malaria vaccines. A strong dissemination and communication plan has been planned to maximise potential impacts of this study and to raise of the project among target audience
Project MVPE-CC at a Glance
Timeline
The Malaria Vaccine Pilot Evaluation Case Control Project (MVPE-CC) began on April 1, 2021, and it will end on June 30, 2024.
Coordinator
Kintampo Health Research Center
(Dr.Kwaku Poku Asante)
Funder
European and Developing Countries Clinical Trials Partnership (EDCTP) is funding this study
Funding (Euro)
3,210,118.75
Keywords
Malaria, Vaccines, Case-Control study, Safety, Effectiveness, Stakeholder engagement
EDCTP Visits Kintampo Health Research Centre (KHRC)
On October 2, 2023, KHRC received a visit from the European and Developing Countries Clinical Trials Partnership (EDCTP), funders of the ongoing Malaria Vaccine Pilot Evaluation- Case Control studies (MVEP-CC) in Ghana, Kenya, and Malawi.
Staff of the Malaria Vaccine Pilot Evaluation-Case Control (MVPE-CC) study had a refresher training on 26th May, 2023.
The MVPE-CC Ethics Advisor (Dr Abraham Hodgson) completed field monitoring visit to Malawi from 7 – 10 March..
MVPE-CC Ethics Advisor completes monitoring visit to Malawi
The MVPE-CC Ethics Advisor (Dr Abraham Hodgson) completed field monitoring visit to Malawi from 7 – 10 March..
MVPE-CC consortium participates in Malaria Vaccine Implementation Programme (MVIP) Investigators meeting in Malawi
From 13-16 March 2023, the MVPE-CC consortium participated in the World Health Organization MVIP Investigators meeting in Lilongwe,